Catalog No.S4667 Synonyms: Lidocaine HCL, Lidothesin, Lignocaine hydrochloride, Xyloneural
Molecular Weight(MW): 270.8
Lidocaine hydrochloride is a local anesthetic and cardiac depressant used as an antiarrhythmia agent.
Purity & Quality Control
Choose Selective EGFR Inhibitors
|Description||Lidocaine hydrochloride is a local anesthetic and cardiac depressant used as an antiarrhythmia agent.|
Lidocaine above 1.25 g/l reduces cellular viability and triggers apoptosis in HCE cells in a time- and dose-dependent manner. Lidocaine-induced apoptosis is caspase dependent and may be related to mitochondrial pathway. Lidocaine, at the level of tissue concentration under topical or local administration, also has a direct inhibitory effect on the activity of epidermal growth factor receptor (EGFR), which is a potential target for antiproliferation in cancer cells.
|In vivo||Intravenous administration of the local anaesthetic lidocaine has been used to treat neuropathic pain for several decades and significantly improves postoperative pain associated with complex spine surgery and cholecystectomy. It is well established that lidocaine used for regional anaesthesia blocks impulses in peripheral nerves by inhibiting voltage-gated sodium (Na+) channels. Intravenous lidocaine has an analgesic effect on mechanical noxious response, decreases the spinal noxious response induced by peripheral pinch stimuli and the frequency of spontaneous excitatory postsynaptic currents(EPSCs) without changing their amplitude. It has no effect on spontaneous inhibitory postsynaptic currents and produces an outward current in SG neurons.|
|In vitro||DMSO||54 mg/mL (199.4 mM)|
|Water||54 mg/mL (199.4 mM)|
|Ethanol||54 mg/mL (199.4 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Synonyms||Lidocaine HCL, Lidothesin, Lignocaine hydrochloride, Xyloneural|
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03310970||Recruiting||Healthy||Nicole K Brogden|Long Island University|University of Iowa||March 7 2018||Phase 4|
|NCT03354312||Active not recruiting||Periodontitis||Chemische Fabrik Kreussler & CO GmbH|Anfomed GmbH||December 5 2017||Phase 4|
|NCT03361397||Not yet recruiting||Airway Complication of Anesthesia||Assiut University||November 30 2017||Not Applicable|
|NCT02236260||Completed||Parkinson''s Disease||Nantes University Hospital||September 3 2014||Not Applicable|
|NCT03720119||Completed||Wound Healing Disorder||SOFAR S.p.A.||January 27 2015||--|
|NCT03096444||Terminated||Pruritus||Gil Yosipovitch|University of Miami||May 23 2017||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.